Molecular Partners AG ADR MOLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
-
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
-
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
Trading Information
- Previous Close Price
- $4.58
- Day Range
- $4.60–5.02
- 52-Week Range
- $3.32–12.70
- Bid/Ask
- $4.60 / $5.07
- Market Cap
- $166.63 Mil
- Volume/Avg
- 730 / 16,309
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.66
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 167
Comparables
Valuation
|
Metric
|
MOLN
|
ACIU
|
BPMC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.96 | 2.43 | 17.47 |
Price/Sales | 18.66 | 17.93 | 15.31 |
Price/Cash Flow | — | — | — |
Price/Earnings
MOLN
ACIU
BPMC
Financial Strength
|
Metric
|
MOLN
|
ACIU
|
BPMC
|
|---|---|---|---|
Quick Ratio | 14.30 | 1.76 | 3.48 |
Current Ratio | 14.58 | 1.80 | 3.71 |
Interest Coverage | −2,135.72 | −510.88 | −8.43 |
Quick Ratio
MOLN
ACIU
BPMC
Profitability
|
Metric
|
MOLN
|
ACIU
|
BPMC
|
|---|---|---|---|
Return on Assets (Normalized) | −26.66% | −31.57% | −24.11% |
Return on Equity (Normalized) | −29.63% | −40.35% | −104.04% |
Return on Invested Capital (Normalized) | −31.38% | −40.68% | −41.57% |
Return on Assets
MOLN
ACIU
BPMC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kxvmljwhc | Jmxvc | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pspwmrkc | Ysbgty | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bgqmnrv | Tttrfbf | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zpkdnyr | Ncgggx | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Dmrvqrlf | Hgc | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Gsxgyslt | Cdynb | $29.2 Bil | |||
| Moderna Inc
MRNA
| Xnkgvpct | Jkrrk | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Xtqfwjjyd | Hvs | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qvnjcgtf | Swycp | $13.2 Bil | |||
| Incyte Corp
INCY
| Fnrzqfym | Hglqyk | $13.0 Bil |
United States